Guía clínica del carcinoma urotelial de vejiga no músculo-invasivo de la Asociación Europea de Urología. Actualización de 2011

Babjuk, M.; Oosterlinck, Willem; Sylvester, Richard; Kaasinen, Eero; Böhle, Andreas; Palou-Redorta, J.; Rouprêt, Morgan

doi:10.1016/j.acuro.2011.12.001

Cited by 58 publications

(18 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 1 ] At presentation, 85% of patients have nonmuscle invasive bladder cancer (NMIBC) which compromises stages Tis, Ta and T1. [ 2 ] Despite complete gross resection, bladder cancer has a high rate of recurrence (50–70%) within 5 years, and up to 20% of NMIBC will progress to muscle-invasive disease and require radical treatment. [ 3 ] Thus, early diagnosis, complete resection, and close surveillance are essential to reduce disease progression and morbidity from radical treatment.…”

Section: Introductionmentioning

confidence: 99%

Diagnostics techniques in nonmuscle invasive bladder cancer

Soubra

2015

Indian J Urol

View full text Add to dashboard Cite

Introduction:Nonmuscle invasive bladder cancer (NMIBC) is the most common presentation of bladder cancer and is often treatable with endoscopic resection and intravesical therapies. Cystoscopy and urine cytology are the gold standard in diagnosis and surveillance but are limited by their sensitivity in some situations. We seek to provide an overview of recent additions to the diagnostic armamentarium for urologists treating this disease.Methods:Articles were identified through a literature review of articles obtained through PubMed searches including the terms “bladder cancer” and various diagnostic techniques described in the article.Results:A variety of urinary biomarkers are available to assist the diagnosis and management of patients with NMIBC. Many have improved sensitivity over urine cytology, but less specificity. There are certain situations in which this has proved valuable, but as yet these are not part of the standard guidelines for NMIBC. Fluorescence cystoscopy has level 1 evidence demonstrating increased rates of tumor detection and prolonged recurrence-free survival when utilized for transurethral resection. Other technologies seeking to enhance cystoscopy, such as narrow band imaging, confocal laser endomicroscopy, and optical coherence tomography are still under evaluation.Conclusions:A variety of urine biomarker and adjunctive endoscopic technologies have been developed to assist the management of NMIBC. While some, such as fluorescence cystoscopy, have demonstrated a definite benefit in this disease, others are still finding their place in the diagnosis and treatment of this disease. Future studies should shed light on how these can be incorporated to improve outcomes in NMIBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostics techniques in nonmuscle invasive bladder cancer

Soubra

2015

Indian J Urol

View full text Add to dashboard Cite

show abstract

“…Risk factors for developing bladder cancer include cigarette smoking, exposure to arsenic, occupation in rubber or fossil oil industry, and schistosomiasis, and chronic inflammatory disease (Steineck, Plato et al 1990). Approximately 70% to 80% of patients with newly diagnosed bladder cancer will present as noninvasive papillary transitional-cell carcinomas (TCCs), 70% of which will recur, and 10 -20% of which will progress and invade the bladder wall (Babjuk, Oosterlinck et al 2012). Those who do present with superficial, noninvasive bladder cancer can often be cured, and those with deeply invasive disease can sometimes be cured by surgery, radiation therapy, or a combination of modalities that include chemotherapy.…”

Section: Immunotherapy In Non-advanced Urothelial Carcinomamentioning

confidence: 99%

“…Transurethral resection of bladder tumor (TURBT) is the standard initial therapeutic approach for diagnosis and treatment of nonmuscle invasive bladder cancer (NMIBC) (Babjuk, Oosterlinck et al 2012) (Williams, Hoenig et al 2010) (Brausi, Witjes et al). However, although TURBT is an effective therapy, up to 45% of patients will experience tumor recurrence within 1 year after TURBT alone (Hall, Chang et al 2007).…”

Section: Immunotherapy In Non-advanced Urothelial Carcinomamentioning

confidence: 99%

Autologous Immunotherapy as a Novel Treatment for Bladder Cancer

Schumacher¹,

Sherif²

2013

Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment

View full text Add to dashboard Cite

“…Current estimates suggest that as many as 75-80% of patients with bladder cancer present for the first time with localized non-muscle invasive bladder cancer (NMIBC). It is further estimated that of those newly diagnosed NMIBC cases, 70% present with what the European Association of Urologists classifies as low-risk disease (2).…”

Section: Been Previously Characterized As An Integrin-specific Oncolymentioning

confidence: 99%

“…The perceived clinical benefit-torisk ratio argument seems justified given that while patients with low-and intermediate-risk NMIBC have a high rate of recurrence, the initial risk of progression is low (0.8% and 6% at 5 years, respectively) (2). However, the risk of progression increases with the number and interval of recurrences, so any initial prevention or delay of recurrence would be of clear benefit (2). Moreover, because of the high rate of recurrence, frequent monitoring and treatment are required, making NMIBC one of the most expensive cancer types to treat over the course of the disease (7).…”

Section: Been Previously Characterized As An Integrin-specific Oncolymentioning

confidence: 99%

A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival

Hancock

McGuire

Tsuji

et al. 2016

View full text Add to dashboard Cite

Abstract. Background/Aim: VAX014 minicells (VAX014) Bladder cancer ranks second amongst newly diagnosed urothelial carcinomas worldwide, is the sixth leading cause of cancer death and the fourth most common malignancy of men in developed countries (1). Current estimates suggest that as many as 75-80% of patients with bladder cancer present for the first time with localized non-muscle invasive bladder cancer (NMIBC). It is further estimated that of those newly diagnosed NMIBC cases, 70% present with what the European Association of Urologists classifies as low-risk disease (2).Current recommended clinical practice for the treatment of low-risk NMIBC is cystoscopic transurethral resection of bladder tumor (TURBT) followed by an immediate postoperative intravesical instillation of a chemotherapeutic agent. Without adjuvant treatment, as many as 35.8% of patients treated for low-risk NMIBC will suffer recurrence within 2 years (3). There have been several studies and meta-analyses published indicating that the immediate postoperative instillation of adjuvant therapy may lead to a decrease in the overall risk of recurrence of up to 39%, with absolute reduction in recurrence rates as high as 17% (4). While clearly effective in reducing recurrence, several recently conducted surveys have revealed that immediate single-dose post-operative adjuvant therapy is not consistently administered (5, 6). A prominently cited reason among those clinicians who do not administer immediate post-operative chemotherapy is that the potential for systemic exposure and agent-associated toxicity outweighs the clinical benefit, especially in cases where bladder perforation is suspected. The perceived clinical benefit-torisk ratio argument seems justified given that while patients with low-and intermediate-risk NMIBC have a high rate of recurrence, the initial risk of progression is low (0.8% and 6% at 5 years, respectively) (2). However, the risk of progression increases with the number and interval of recurrences, so any initial prevention or delay of recurrence would be of clear benefit (2). Moreover, because of the high rate of recurrence, frequent monitoring and treatment are required, making NMIBC one of the most expensive cancer types to treat over the course of the disease (7). Therefore, an effective agent for use in the immediate post-operative setting would impart considerable pharmacoeconomic benefit. Recent failures in mid-and late-stage clinical trials highlight the unmet clinical need for the development of new agents that can be safely administered in the immediate post-operative setting (8).

show abstract

Guía clínica del carcinoma urotelial de vejiga no músculo-invasivo de la Asociación Europea de Urología. Actualización de 2011

Cited by 58 publications

References 66 publications

Diagnostics techniques in nonmuscle invasive bladder cancer

Diagnostics techniques in nonmuscle invasive bladder cancer

Autologous Immunotherapy as a Novel Treatment for Bladder Cancer

A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival

Contact Info

Product

Resources

About